Results 131 to 140 of about 14,279 (236)

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects

The molecular mechanism by which hypolipidemic fibrates and antidiabetic thiazolidinediones exert their hypotriglyceridemic action are discussed.
Staels, B., Auwerx, J., Fruchart, J. C., Schoonjans, K.   +3 more
core   +1 more source

BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile

Frontiers in Chemistry
BAR502, a bile acid analogue, is active as dual FXR/GPBAR1 agonist and represents a promising lead for the treatment of cholestasis and NASH. In this paper we report the synthesis and the biological evaluation of a library of hybrid compounds prepared by
Claudia Finamore, Simona De Marino, Chiara Cassiano, Giuliano Napolitano, Pasquale Rapacciuolo, Silvia Marchianò, Michele Biagioli, Rosalinda Roselli, Cristina Di Giorgio, Carmen Festa, Stefano Fiorucci, Angela Zampella   +11 more
doaj   +1 more source

s-Fibrations [PDF]

Fundamenta Mathematicae, 1980
Husch, L. S., Stoughton, J. R.
openaire   +2 more sources

Fibrates : Do They Still Have a Role in Therapy in 2025?

Purpose of Review: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of mortality despite opti mal LDL-C control, leaving substantial residual risk in patients with atherogenic dyslipidaemia.
Pirillo, Angela, Catapano, Alberico L., Zambon, Alberto   +2 more
core   +1 more source

Conformational behaviour, intra-molecular hydrogen bonding, gas phase acidities and hydrolysisstudy of fibrate-type antihyperlipidemic drugs

Current Issues in Pharmacy and Medical Sciences, 2012
A theoretical study on fibrate-type drugs in gas phase is presented. All stable conformations of fibric acid (as common and active moiety of these drugs) were identified and optimized at B3LYP/6-31+g(d) level.
Łukasz Komsta, Robert Skibiński, Anna Maria Gierczak   +2 more
doaj  

Peroxisome Proliferator‐Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

JGH Open
Objective Peroxisome proliferator‐activated receptor (PPAR) agonists are agents used for patients with primary biliary cholangitis (PBC) who do not respond to conventional agents like ursodeoxycholic acid (UDCA).
Maadeha H. Zaidi, Zaroon Haider, FNU Sadia, Muhammad Tayyab, Muhammad Naveed Tariq, Hasaan H. Ans, Muhammad Bilal Javaid, Ahmad Khan, Muhammad Hassan Ahmad, Rahman Rasheed, Uzair Jafar, Huzaifa Ahmad Cheema, Asma'a Munasar Ali Alsubari, Muhammad Shahzil, Essam Rashad, Rehmat Ullah Awan, Hassam Ali, Prasun K. Jalal   +17 more
doaj   +1 more source

Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status

, 2016
Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 statusObjective A significant residual cardiovascular risk is consistently observed in patients treated with statins.
Jordi Camps; Amirhossein Sahebkar; Anna Hernández-Aguilera; David Abelló; Elena Sancho; Jorge Joven
core  

Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review

, 2013
Fibrates are used as lipid-lowering drugs to prevent cardiovascular pathology. Fibrates are ligands of peroxisome proliferator-activated receptor α (PPARα).
Lubberts, E.W. (Erik), Jenniskens, Yvonne, Verhaar, J.A.N. (Jan), Verhaar, Jan, van Osch, Gerjo, Clockaerts, Stefan, Lubberts, Erik, Bierma-Zeinstra, S.M. (Sita), van Eekeren, ICM (Inge C. M.), Eekeren, I.C.M. (Inge C. M.) van, Bierma - Zeinstra, Sita, Clockaerts, S. (Stefan), Bastiaansen-Jenniskens, Y.M. (Yvonne), Osch, G.J.V.M. (Gerjo) van   +13 more
core   +1 more source

HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 1. NON-STATIN HYPOLIPIDEMIC MEDICATIONS

Атеросклероз, 2016
This article is devoted to discussion about main aspects of current use of non-statin hypolipidemic drugs according last international guidelines (including fibrates, nicotinic acid, resins, polyunsaturated fatty acids, ezetimibe, PCSK9-inhibitors).
A. E. Bagriy, A. I. Dyadyk, M. V. Khomenko, I. N. Tsiba, V. A. Efremenko, E. V. Shchukina, O. A. Prikolota   +6 more
doaj  

Pharmacokinetic interactions between statins and fibrates

, 2005
Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or ...
S. Bellosta, A. Corsini, M. H. Davidson
core   +1 more source